Acute bronchitis, community-acquired pneumonia (outpatient, ward, intensive care) and nosocomial pneumonia (limited or broad spectrum) side by side: who belongs in each setting, the likely pathogens, the empiric regimen and what to watch. No doses.
| Setting | Who belongs here | Likely pathogens | Empiric regimen | Notes | Source |
|---|---|---|---|---|---|
| Acute bronchitis | Inflammation of one or more bronchi, sparing the bronchioles and alveoli; acute at any age, chronic mainly in chronic obstructive pulmonary disease | Viruses (rhinovirus, coronavirus, influenza, adenovirus); occasionally bacteria (Mycoplasma pneumoniae, Chlamydia pneumoniae, Bordetella pertussis, streptococci, staphylococci, Haemophilus), sometimes after a viral illness | Supportive care; routine antibiotics not recommended. Symptoms beyond 5 days: consider bacteria — doxycycline (preferred if Mycoplasma is documented, because of macrolide resistance) or a macrolide | Possibly avoid antihistamines and sympathomimetics; avoid a respiratory fluoroquinolone unless there was recent antibiotic exposure | L11 slide 8 slide 5 slide 6 slide 7 |
| Community-acquired, outpatient, no resistance risk | No risk factor for resistant S. pneumoniae | S. pneumoniae, M. pneumoniae, H. influenzae, Moraxella catarrhalis, respiratory viruses | First line: a macrolide (azithromycin, clarithromycin). Second line: doxycycline, minocycline | Empiric therapy; diagnostic tests not routinely performed. Current guidelines differ (see the note below). | L11 slide 14 slide 12 slide 11 |
| Community-acquired, outpatient, resistance risk | Age over 65, a beta-lactam in the past 3 months, alcoholism, immunosuppression, comorbidities, a child in day care at home | Penicillin-resistant S. pneumoniae on top of the outpatient list | Beta-lactam plus a macrolide (amoxicillin with or without clavulanic acid; cefuroxime or cefpodoxime) or a respiratory fluoroquinolone (levofloxacin, moxifloxacin) | The fluoroquinolone route suits a beta-lactam allergy | L11 slide 14 slide 13 |
| Community-acquired, inpatient (not intensive care) | Admitted to the ward | S. pneumoniae, M. pneumoniae, C. pneumoniae, H. influenzae, Legionella, aspiration, respiratory viruses | Intravenous beta-lactam (cefotaxime, ceftriaxone, high-dose ampicillin) plus an intravenous or oral macrolide, or doxycycline, or a respiratory fluoroquinolone (beta-lactam allergy) | Blood and sputum cultures before antibiotics; sputum gram stain is controversial (often contaminated) | L11 slide 15 slide 12 slide 11 |
| Community-acquired, intensive care | Admitted to the intensive care unit | S. pneumoniae, Staphylococcus aureus, Legionella, gram-negative bacilli, H. influenzae | Same as the ward, all intravenous | Consider MRSA (methicillin-resistant Staphylococcus aureus) coverage if warranted | L11 slide 15 slide 12 |
| Nosocomial, limited spectrum | Pneumonia more than 48 hours after admission, with neither late onset (5 days or more) nor a multidrug-resistant risk factor | Nosocomial pathogens without multidrug resistance; levofloxacin or moxifloxacin if atypical pathogens are a worry | Ceftriaxone, or levofloxacin or moxifloxacin, or ampicillin/sulbactam, or ertapenem | Start at once; streamline when cultures and sensitivities return | L11 slide 22 slide 21 slide 16 |
| Nosocomial, broad spectrum | Late onset (5 days or more) or a multidrug-resistant risk factor: prior antibiotics, colonization, hospitalization or chronic care, immunosuppressive disease or therapy | Gram-negative bacilli (Pseudomonas aeruginosa most common, E. coli, K. pneumoniae, Acinetobacter, Enterobacter, Serratia); gram-positive cocci (MRSA (methicillin-resistant Staphylococcus aureus) most common, S. pneumoniae); fungi (Candida, Aspergillus fumigatus) | Antipseudomonal cephalosporin, carbapenem or penicillin/beta-lactamase inhibitor PLUS an antipseudomonal fluoroquinolone or an aminoglycoside, PLUS vancomycin or linezolid | Must cover MRSA (methicillin-resistant Staphylococcus aureus) and Pseudomonas; do not wait for a definitive culture | L11 slide 23 slide 21 slide 19 slide 20 |
| Nosocomial, after cultures | Cultures and sensitivities are back | The organism grown | Scale back coverage; switch to oral therapy when possible (cheaper) | If it fails: wrong therapy, wrong diagnosis (pulmonary embolus, neoplasm) or a complication (C. difficile colitis, empyema, lung abscess) | L11 slide 31 |